Advances in the management of psoriasis: monoclonal antibody therapies. - Wikidata - wikimedia - TriplyDB

Advances in the management of psoriasis: monoclonal antibody therapies.

Advances in the management of psoriasis: monoclonal antibody therapies.

http://www.wikidata.org/entity/Q35030921

about

Novel biological immunotherapies for psoriasis.The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis.

P2860

Q35164740-940F8E86-B812-43AA-902C-64DF48D63886 Q40800458-5D3442B5-8946-44BE-9BD8-AB3FCEAFA57A

P2860

Advances in the management of psoriasis: monoclonal antibody therapies.

http://www.wikidata.org/entity/Q35030921

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Advances in the management of psoriasis: monoclonal antibody therapies.

@ast

Advances in the management of psoriasis: monoclonal antibody therapies.

@en

type

label

Advances in the management of psoriasis: monoclonal antibody therapies.

@ast

Advances in the management of psoriasis: monoclonal antibody therapies.

@en

prefLabel

Advances in the management of psoriasis: monoclonal antibody therapies.

@ast

Advances in the management of psoriasis: monoclonal antibody therapies.

@en

P1433

Q35030921-3D95E00D-1A53-4742-8EB0-B53F3496114E

P1476

Q35030921-37EA6D2B-B989-40B7-85FF-6A3FCF2EBF28

P2093

Q35030921-002207F5-FDB3-4081-99AC-A538CD479A6E

Q35030921-53C7AA3D-3A7D-4435-B87F-A10B6FD67A9B

Q35030921-6B91C566-0B52-4DC6-8AC0-0E85983B6F3A

Q35030921-A70526D6-677D-43D6-B527-96C829BC7BE8

P2860

Q35030921-010DE6C9-4AE5-43D0-91AD-8AB3C227B2F4

Q35030921-01378C3F-2C49-43E3-8D51-B0ED3710F09D

Q35030921-1BD89B76-C050-4024-9865-3B9BE58CA463

Q35030921-210D1FA8-C1DF-4D11-8336-3ADCE66F3A17

Q35030921-2D44C840-81B5-4F61-BD64-FFB398EF8476

Q35030921-3249A5BF-A46B-492F-8D54-17829EAD172A

Q35030921-3B9E4BD5-4FDE-45D4-BFEE-E842265412A4

Q35030921-40A2758C-A0F0-436E-B900-619EE33F47F3

Q35030921-564E291E-D2BC-4029-8860-686E0070AB99

Q35030921-56B0432A-80D5-4F43-A707-E8E4C7A11CBE

P304

Q35030921-39AF4C64-49EF-45CF-A9BF-53E10AFCAD7B

P31

Q35030921-B510DD71-A525-4B80-9BEC-31FC7982E192

P356

Q35030921-E14948F6-DE6C-4C43-ACB4-914D85C335D6

P433

Q35030921-1E25EAF8-2794-4F88-BE7A-8C07D5CF2699

P478

Q35030921-212CECF0-F64D-41BD-B94F-94025B484D95

P577

Q35030921-CEC24EBF-04A4-4026-B691-C3659A8378ED

P698

Q35030921-A0947F2F-C411-4E79-B91B-198CBBD885B2

P356

J.1365-4362.2002.01662.X

P1433

International Journal of Dermatology

P1476

Advances in the management of psoriasis: monoclonal antibody therapies.

@en

P2093

Calvin O McCall

http://www.w3.org/2001/XMLSchema#string

Don Mehrabi

http://www.w3.org/2001/XMLSchema#string

Joshua B DiCarlo

http://www.w3.org/2001/XMLSchema#string

Seaver L Soon

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

The pathogenesis of psoriasis: immunological facts and speculations.

Review article: safety of infliximab in clinical trials.

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells.

P304

827-835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-4362.2002.01662.X

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12492964

http://www.w3.org/2001/XMLSchema#string